New testing options bring prenatal testing market to the forefront in the U.S.
Global Information Inc. would like to present a new market research report, "Strategic Analysis of the U.S. Prenatal Testing Market" by Frost & Sullivan.
Prenatal testing is an available option for pregnant women around the world to obtain information at their discretion about the fetus they are carrying. Women may choose to detect chromosome abnormalities in the fetus. For example, mothers-to-be are often told by their OBGYNs about the increased risk of chromosomal abnormality with advanced maternal age. In the United States, the trend of increasing maternal age for women may also increase the use of prenatal tests.
Analysis from Frost & Sullivans new research report finds that the market earned revenues of $1.28 billion in 2010 and estimates this to reach $1.59 billion in 2017. In this analysis, Frost & Sullivans in vitro diagnostic (IVD) industry analysts thoroughly examine the following market segments: maternal serum screen, nuchal translucency (NT) ultrasound, karyotype, prenatal fluorescent in situ hybridization (FISH), and prenatal chromosomal array.
"Prenatal diagnostic companies aim to develop tests that give women the information they want about their pregnancy," said Frost & Sullivan Industry Analyst Winny Tan. "Should pregnant women elect prenatal testing, these companies understand that is critical for the test results to be as conclusive and reliable as possible as this is a sensitive and highly personal area."
A sophisticated array of techniques is applied in prenatal testing. Prenatal chromosomal array detects serious chromosomal abnormalities at a resolution that surpasses that of traditional karyotyping. While prenatal microarray requires an invasive procedure such as an amniocentesis, non-invasive prenatal diagnostics (NIPD) may be available in the near future as several companies are focused on bringing NIPD to the market in 2012.
"This industry is witnessing major technological developments," said Tan. "Cutting-edge techniques like Array comparative genomic hybridization (ArrayCGH) and sequence analysis of circulating fetal DNA found in maternal blood are being applied to prenatal testing by companies. Included in Frost & Sullivan research findings is that 60 percent to 70 percent of all pregnancies in the United States receive a maternal serum screen. A much smaller group undergoes diagnostic testing that is invasive."